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Abstract
Background: Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, can be secreted
by most cell types and released in perhaps all biological fluids. EVs contain multiple proteins, specific lipids and
several kinds of nucleic acids such as RNAs and DNAs. Studies have found that EVs contain double-stranded DNA
and that genetic information has a certain degree of consistency with tumor DNA. Therefore, if genes that exist in
exosomes are stable, we may be able to use EVs genetic testing as a new means to monitor gene mutation.
Methods: In this study, EVs were extracted from serum under various storage conditions (4 °C, room temperature
and repeated freeze-thaw). We used western blotting to examine the stability of serum EVs. Then, we extracted
DNA from EVs and tested the concentration changing under different conditions. We further assessed the stability
of EVs DNA s using polymerase chain reaction (PCR) and Sanger sequencing.
Results: EVs is stable under the conditions of 4 °C (for 24 h, 72 h, 168 h), room temperature (for 6 h, 12 h, 24 h,
48 h) and repeated freeze-thaw (after one time, three times, five times). Also, serum DNA is mainly present in EVs,
especially in exosomes, and that the content and function of DNA in EVs is stable whether in a changing environment
or not. We showed that EVs DNA stayed stable for 1 week at 4 °C, 1 day at room temperature and after repeated
freeze-thaw cycles (less than three times). However, DNA from serum EVs after 2 days at room temperature or after five
repeated freeze-thaw cycles could be used for PCR and sequencing.
Conclusions: Serum EVs and EVs DNA can remain stable under different environments, which is the premise that EVs
could serve as a novel means for genetic tumor detection and potential biomarkers for cancer diagnostics and
prognostics.
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Background
Extracellular vesicles (EVs) are cell-derived membrane
vesicles, including exosomes, microvesicles, and other
types of membrane vesicles [1]. The best studied of these
vesicles are exosomes. Exosomes are nanometer-sized
EVs of endocytic origin that are secreted by most cell
types, under physiological and pathological conditions
upon fusion of multivesicular bodies (MVBs) with the
plasma membrane (PM) [2–5]. Recent studies have
shown that exosomes can be released in many and per-
haps all biological fluids, including blood [6], urine [7],
cerebrospinal fluid [8] breast milk [9], malignant ascites
[10, 11], saliva [12], tears [13], nasal secretions [14],
semen [15], amniotic fluid [16], bronchoalveolar lavage
fluid [17] and culture medium supernatant in cell cul-
tures [3]. Although the term exosome was originally
raised in 1981 [18], interest in these EVs has increased
dramatically in the last few years, after researchers found
that they predominantly contain RNA, proteins, and
lipids [19], which can reflect the functionality of the host
cell and possess molecular signatures or footprints re-
sembling the cell from which they were secreted [20].
Therefore, the EVs has emerged as an important novel
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mediator in facilitating intercellular communication by
regulatory molecules in its cargo and inducing physio-
logic and genetic changes in targeted cells [21].
Compared with different types of RNA, such as mes-
senger RNA (mRNA), microRNA, and noncoding RNA
(ncRNA), which have been shown in the Exocarta data-
base [19], less is known about EVs DNA content, al-
though some types of DNA have been reported, such as
single-stranded DNA (ssDNA) [22], mitochondrial DNA
(mtDNA) [23] and plasmid DNA (pDNA) [24]. The
question remains as to whether the DNA cargo is ran-
domly sorted or if it is systematically packed into EVs. A
recent report by Mark et al. found that exosomes
contain double-stranded DNA (dsDNA)and that exo-
some DNA can serve as a novel biomarker for cancer
detection [25]. Furthermore, an increasing number of
studies have emerged showing that different types of
DNA in EVs may be associated with various biological
functions [26–28].
It is well-known that exosomes contain dsDNA. Also,
exosomal DNA (exoDNA) comprises the entire genome,
which spans all chromosomes [29] and carries on the
mutational status of malignant parental cells [25]. The
question is whether exosomes can be utilized as scape-
goats for tumor cells to harbor tumor-specific genetic
mutations similar to other sources of circulating tumor
DNA (ctDNA) [30]. If these assumptions are established,
the feasibility of exosomes as new tumor detection indi-
cators will then became a critical question. As we have
described above, EVs are widely distributed in various
body fluids systems, which make them more accessible
than tumor cells. Moreover, if EVs prove to have consid-
erable stability in vitro, they will become the most prom-
ising and available samples for cancer genetic detection.
In the present study, we extracted DNA of EVs from the
blood of cancer patients under different conditions, and
its stability was evaluated.
Methods
Serum samples
A collection of serum samples was approved by the local
ethics committee of the Affiliated Hospital, Academy of
Military Medical Sciences. A written informed consent
for the serum sampling was obtained preoperatively
from all patients with the disclosure of planned analyzes
regarding potential prognostic markers.
Isolation of EVs from serum
Peripheral blood samples from patients with metastatic
colorectal cancer (mCRC) were centrifuged at 3 000 g
for 15 min at ambient temperature (within 2 hours of
the blood drawing) to remove cells and cell debris. EVs
were isolated from the serum using ExoQuick reagent
(System Biosciences, Palo Alto, California, USA) [31] or
PureExo® Exosome Isolation Kit (101 Bio, Palo Alto,
California, USA). For ExoQuick isolation, 120 μl Exo-
Quick reagents was added to 500 μl serum and precipi-
tated 30 min at 4 °C. Precipitated samples were
centrifuged at 1 500 g for 30 min at room temperature.
120 μl ExoQuick reagent was added to the supernatant
and precipitated at 4 °C for another 30 min. Precipi-
tated samples were centrifuged at 1 500 g for 30 min at
room temperature. The pooled EVs pellets were dis-
solved in the appropriate buffer for DNA or protein
analysis. For PureExo® Exosome Isolation Kit, EVs were
extracted from 500 μl serum according to the instruc-
tions in step.
Transmission electron microscopy
EVs samples (10 μl) resuspended in phosphate buffer sa-
line (PBS) were applied to 300 mesh carbon-coated cop-
per grids for 10 min. Excess samples were blotted with
filter paper and then negatively stained with 10 μl of a
2 % aqueous uranyl acetate solution for 3 min. Stain was
blotted dry from the grids with filter paper, and samples
were allowed to dry. Samples were then examined in a
HITACHI H-7650 transmission electron microscope
(HITACHI, Tokyo, Japan) at an accelerating voltage of
80 kV.
Proteins extraction and quantification
EVs samples from 500 μl of serum were lysed in 200 μl
RIPA buffer [65 mM Tris-HCl pH 7.4, 150 mM NaCl,
1 mM EDTA, 1 % NP-40, 0.25 % sodium deoxycholate,
protease inhibitors cocktail (Roche Diagnostics, Mann-
heim, Germany), and phosphatase inhibitor (Biomed,
Beijing, China)] and incubated at 0 °C for at least
30 min. Incubated specimens were then centrifuged at
12,000 rpm for 30 min at 4 °C. Protein concentration
was analyzed by the Pierce™ BCA protein assay kit
(Thermo Fisher Scientific, Wilmington, Delaware, USA).
Western blotting
A total of 10 μg exosomal proteins were loaded on a
regular SDS-PAGE gel. Following electrophoresis, gels
were transferred to PVDF (polyvinylidene fluoride)
membranes (Millipore, Billerica, USA) for western blot-
ting. Membranes were blocked with 5 % nonfat dry milk
dissolved in 1 × PBST (PBS plus 0.2 % v/v Tween-20) for
2 h at room temperature, probed with antigen-specific
antibodies overnight at 4 °C and washed with 1 × PBST
solution three times. Afterward, membranes were incu-
bated with secondary antibodies for 1 h at room
temperature and washed with 1 × PBST solution three
times. Blots were developed with chemiluminescent re-
agents from Pierce (Thermo Fisher Scientific).
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DNA isolation
Before the DNA isolation, samples were treated with
2000 U/ml DNase I (New England BioLabs, Frankfurt,
Germany) for 2 h at 37 °C to remove possible nucleic
acid contaminants. After treatment, the enzymes were
heated to the condition of inactivation at 75 °C for
10 min (this step reaction was only used to verify the
distribution of serum DNA). First, total DNA was ex-
tracted from EVs by using DNA lysis buffer [0.5 % SDS,
0.05 M EDTA, 0.01 M Tris-HCl pH 8.0, 0.1 M NaCl,
200 μg/ml Protease K (Amresco, Solon, Ohio, USA)]. A
total of 400 μl DNA lysis buffer was added to each tube
of EVs. After mixing, the samples were incubated for
24 h at 55 °C. The serum that EVs had been extracted
out of did not need the process above. Second,
deproteinization was performed using a balance of phe-
nol and chloroform. Third, DNA was precipitated using
3 M CH3COONa, glycogen and absolute ethanol for
24 h at −20 °C and resuspended DNA with TE (0.001 M
EDTA, 0.01 M Tris-HCl pH 8.0) at 37 °C for at least
16 h. The EVs DNA was quantified on a Nano Drop
ND-2000 Spectrophotometer (Thermo Fisher Scientific).
PCR analysis and sequencing
The polymerase chain reaction (PCR) analysis was per-
formed with preamplified DNA products from EVs and
serum disposed of EVs samples from patients with dif-
ferent conditions by using specifically designed primers
(Table 1). Each experiment has repeated a minimum of
three times. The PCR reaction mixture contained 25 μl
2 × Taq Master Mix (Sino Bio Technologies, Shanghai,
China), 2 μl 1 × primer, 4 μl resuspended DNA and
double-distilled water up to 50 μl (100 mM dNTP mix,
10 mM of each primer, 5 U/ml of Taq 5000 DNA poly-
merase). PCR was performed in a C1000™ Thermal
Cycler (Bio-Rad, Hercules, California, USA) and the
Table 1 Primers used in PCR reactions




Fig. 1 Morphological characterization and size distribution of EVs. a Micrograph of serum exosomes with low-magnification TEM; b High
resolution TEM examination outcomes; c, d Size distribution of the isolated EVs analyzed by TEM and Image-pro Plus. The EVs were counted three
times, and the data represented mean ± SD. EVs were extracted by ExoQuick reagent (c) or by PureExo® Exosome Isolation kit (d)
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thermal cycles were as follows: 1 cycle of 2 min at 94 °C,
30 cycles for 30 s at 94 °C, 30 s at 58 °C and 30 s at 72 °C,
and 5 min at 72 °C. The resulting PCR products were
validated by electrophoresis using 3 % agarose (Amresco)
gels. PCR products were sent to Invitrogen Biotechnology
to conduct the sequencing analysis.
Results
Extraction and identification of serum EVs
We used two different methods to isolate EVs, one of
which was the ExoQuick reagent and the other one was
Exosome Isolation Kit. Studies have shown that Exo-
Quick reagent could extract most EVs from blood sam-
ples [32, 33] and Exosome Isolation kit could capture
most exosomes from serum [34] and that according to
the study of 101Bio, using their kit could get 95 % exo-
some purity. To confirm whether EVs were extracted
successfully by the two methods above, harvested serum
EVs were analyzed by transmission electron microscopy
(TEM) [35]. Particles between 20 and 170 nm were iden-
tified (Fig. 1a, b). The average size of EVs observed in 40
captured images by TEM was 90 ± 3 nm; most vesicles
were between 40 and 140 nm in diameter, with a peak
around 80–100 nm whether the extraction process using
ExoQuick reagent (Fig. 1c) or Exosome Isolation Kit
(Fig. 1d). There was no significant difference in the size
of the EVs obtained by two methods. So we concluded
that the main parts of EVs in serum were exosomes, and
we used ExoQuick reagent for EVs extraction taking into
account the simplicity of the operation in the follow-up
test processes. To ensure that the EVs derived from
serum were enriched in exosomes, the isolated vesicles
were subjected to exosomal marker analysis. The results
of the western blotting (Fig. 2a) showed that only serum
(serumEV+) and EVs contain CD63 and TSG101, which
are specific markers of exosomes [36]. However, a serum
that had been extracted for EVs (serumEV-) did not con-
tain CD63 and TSG101. In addition, albumin, as a ubi-
quitous protein outside of EVs, mainly existed in
serumEV+ and serumEV. Therefore, we extracted the
overwhelming majority of serum EVs (especially exo-
somes) in the blood sample and proved that the EVs ex-
traction process was successful.
Serum DNA dominates in EVs
Since serum contains different types of DNA, such as
cfDNA, ctDNA and exoDNA [26], the extraction
process of EVs DNA must reduce external DNA con-
tamination. Two volunteers were randomly selected, and
we took two tubes of identical serum samples from each
of them to extract EVs. Before the DNA extraction, one
copy of EVs and EVs-depleted serum of each patient
were treated extensively with DNase I simultaneously,
and the other samples remain undisposed.
We amplified three fragments of KRAS, EGFR and p53
(Table 1) from EVs DNA to analyze whether DNA is as-
sociated with the outer membrane or inside the EVs. We
found that with or without DNase I treatment the pat-
tern from each sample was similar (Fig. 2b). And that
the DNA gene amplification results were negative in the
serumEV- even the conditions were complete as same as
EVs. This result indicated that EV specific DNA predom-
inates in serum DNA.
EVs are stable in different environments
To assess the impact of disparate storage temperature
and different storage time on the stability of EVs, ran-
domly selected freshly isolated serum (after centrifuga-
tion of peripheral blood) from three advanced colorectal
cancer (CRC) patients was immediately stored at 4 °C
(for 24 h, 72 h, 168 h), room temperature (for 6 h, 12 h,
24 h, 48 h) and −80 °C with different freeze-thaw cycles
(1 time, 3 times, 5 times). EVs were extracted from the
Fig. 2 Serum DNA predominates in EVs. a EVs were characterized by
the exosome specific expression of CD63 and TSG101 by western
blotting. b EVs DNA isolated from serum pretreated with DNase I or
not was detected by PCR amplification. SerumEV+ represents EVs-
contained serum, SerumEV- represents EVs-depleted serum
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stored serum respectively. The serum volume of each
patient under different conditions was consistent. An
equal volume of proteins, under various conditions,
from either EVs (Fig. 3a, b) or EVs-depleted serum
(Fig. 3c) was used for western blotting with antibodies
specific for CD63. Our results showed that CD63 and
TSG101 remained unchanged in EVs exposed to differ-
ing environments. Also, as time went on, we detected
trace amounts of CD63 on membranes in EVs-depleted
serum. We also incubated the membranes, which had
previously been exposed to CD63, with an anti-human
albumin antibody. As expected, a clear chromogenic al-
bumin emerged in the EVs-depleted serum films
(Fig. 3d). Overall, we concluded that the EVs remained
stable in serum exposed to differing environments.
EVs DNA is stable under different conditions
Since serum DNA dominates in EVs (Fig. 2b), we
next asked whether EVs DNA was stable under vari-
ous conditions. Therefore, we verified the concentra-
tion of EVs DNA, which was isolated from the EVs
mentioned above. As seen in Fig. 4, we detected vari-
ations of EVs DNA concentration among the different
patient samples. EVs DNA that was extracted from
serum which had been stored at 4 °C was relatively
stable (Fig. 4a), in spite of the fact that the concen-
tration of EVs DNA began to decline slowly after
72 h. And apparently, a decrease of concentration
from 24 to 48 h was observed in samples that had
been stored at room temperature (Fig. 4b). However,
EVs DNA that was subjected to freeze-thaw cycles de-
clined dramatically from 0 to 5 times freeze-thaw
(Fig. 4c). In comparison to the two cases above, exo-
somes seemed to be more fragile after freeze-thaw.
The observed changes that occurred in PCR (polymer-
ase chain reaction) products were consistent with the
EVs DNA concentration (Fig. 5). EVs DNA stayed stable
for 1 week at 4 °C (Fig. 5a), 1 day at room temperature
(Fig. 5b) and repeated freeze-thaw three cycles (Fig. 5c),
even though there were slight differences among pa-
tients and primers. Also, the PCR products of EVs-
depleted serum gradually increased, accompanied by
vesicle rupture under a variety of extreme conditions. In
summary, these results show that EVs DNA is extremely
stable, especially at 4 °C.
EVs provides an attractive means for gene detection
We collected serum samples from two CRC patients. By
histological examination, we determined that one CRC
patient had a mutated form of the KRAS gene and the
other patient was wild-type. The extraction conditions of
the EVs were as follows: 0 h after the blood was centri-
fuged, 4 °C for 168 h, room temperature for 48 h and
five freeze-thaw cycles. EVs DNA was isolated from
serum that was stored under the above conditions, and
the KRAS and p53 PCR products were sequenced
(Table 1). Simultaneously, we extracted the leukocytes
from these two CRC patients to use for control. Our re-
sults showed that PCR amplification from EVs DNA was
successful regardless of storage conditions (Fig. 6). The
sequencing results showed no significant difference
among the different storage conditions compared with
the freshly prepared samples (Fig. 6). Moreover, after the
5-time freeze-thaw cycle, there was a significant decrease
Fig. 3 Immunoblot of exosome specific markers in EVs and EVs-depleted serum under different conditions. a Immunoblot of CD63 in EVs from
the serum of three CRC patients under different conditions. b Immunoblot of TSG101 in EVs from the serum of three CRC patients under different
conditions. c Immunoblot of CD63 in EVs-depleted serum from three CRC patients under different conditions. d Immunoblot of albumin in
EVs-depleted serum from three CRC patients under different conditions. Freshly isolated serum randomly selected from three advanced CRC
patients was stored at 0 h, 4 °C (24 h, 72 h, 168 h), room temperature (6 h, 12 h, 24 h, 48 h) and −80 °C with freeze-thaw (one time, three times,
five times)
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in the sequencing peak values in the samples containing
the mutant KRAS gene locus and the wild-type KRAS
locus (Fig. 6). Therefore, we conclude that the repeated
freeze-thaw condition has the largest impact on the sta-
bility of EVs. However, no matter what condition was
analyzed, the KRAS mutation was detected in the EVs
DNA, although the sequencing peak value was different
(Fig. 6). Furthermore, the genetic testing results between
exosomes and tumor cells showed a high degree of
consistency. Patient tumor DNA that showed a mutation
in exon 2 of the KRAS gene by histological examination
showed the same mutation by sequencing in the patient’s
Fig. 5 Amplification of KRAS and EGFR in EVs and EVs-depleted serum under different conditions. a KRAS and EGFR were amplified in EVs and EVs-
depleted serum from the serum of three patients stored at 4 °C for 0, 24, 72 and 168 h. b KRAS and EGFR were amplified in EVs and EVs-depleted
serum from the serum of three patients stored at room temperature for 0, 6, 12, 24 and 48 h. c KRAS and EGFR were amplified in EVs and EVs-
depleted serum from the serum of three patients after repeated freeze-thaw 0, 1, 3 and five times. SerumEV- represents EVs-depleted serum
Fig. 4 The concentration of EVs DNA extracted from serum under different conditions. a The concentration of EVs DNA from the serum of three
patients stored at 4 °C for 0, 24, 72 and 168 h. b The concentration of EVs DNA from the serum of three patients stored at room temperature for
0, 6, 12, 24 and 48 h. c The concentration of EVs DNA from the serum of three patients after repeated freeze-thaw 0, 1, 3 and five times
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EVs DNA. Moreover, no mutations were detected in the
somatic cells of patients. In summary, our results sug-
gest that exosomes can be used as an ideal material for
gene detection.
Discussion
Cancer is one of the leading causes of morbidity and
mortality in the world, and the treatment of it has
evolved during the past two decades. Early diagnosing
and effective treatment can significantly reduce cancer
mortality, which relies on accurate diagnosis, precise
tumor staging, and gene mutation status [37]. As mo-
lecular targeted therapy develops, standardized treat-
ment of tumors should depend on the results of gene
detection [38]. Genetic testing of tumor tissues is the
current gold standard for cancer diagnosis and therapy.
Primary lesions and metastatic foci in early tumors are
hard to find. Furthermore, as cancer advances, surgery
and biopsy is rather difficult, and they are both invasive
techniques, which could bring more suffering to the pa-
tient. Importantly, results of genetic tests to help guide
treatment are not necessarily accurate because tumor
tissue is heterogeneous [39]. Therefore, with our current
in-depth study of EVs (especially exosomes), we ushered
in the dawn to solve this problem.
Exosomes from different cell types have different func-
tions, due to the composition of their functional mole-
cules, which varies from their cell of origin [40–42].
Exosomes contain multiple proteins, DNA, mRNA,
microRNA, long noncoding RNA and genetic material
Fig. 6 Sanger sequencing of EVs DNA extracted from serum under different conditions. Sanger sequencing revealed a p53 mutation on codon 72
in EVs DNA from patient 1, a p53 mutation on codon 72 and two KRAS mutations on codon 12 and 13 in EVs DNA from patient 2; white blood
cell (WBC) DNA from the same patient was used as a control
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from viruses/prions [43]. These substances are biochem-
ically and functionally distinct when transferred to a re-
cipient cell where they regulate protein expression and
signaling pathways [44]. Tumor-derived exosomes play
a significant role in facilitating metastases by strength-
ening angiogenesis [45]. Evs are emerging as key
players in intercellular communication between cancer
cells and their microenvironment through horizontal
transfer of information via their cargo [25, 46]. Mean-
while, the more noteworthy fact is, serum exosomes
from cancer patients contain genomic DNA that spans
all chromosomes [29], and that exosomes from cancer
patients have a higher concentration than normal cells
[47, 48]. It is well-known that the stability of exosomes
depends largely on their bilayer lipid membrane struc-
ture to protect biological cargo against degradation
and denaturation in the extracellular environment [49].
The focus of our work is for the stability of EVs DNA
and possibility of being a novel approach for genetic
testing.
In the present study, we tested the stability of serum
EVs by analyzing their molecular markers, DNA con-
centration, PCR amplification, and sequencing from
exoDNA. The membrane bilayer structure is the basis
for the stability of the exosome; therefore, the exoDNA
can be protected from degradation. Similar to mRNA
[50], the exoDNA content remains substantially at a
constant level after experiencing different treatment
conditions. EVs experience a slight rupture with the
length of time and increasing the number or freeze-
thaw cycles. We observed an apparent change in DNA
concentration from 24 to 48 h at room temperature.
However, the change was not significant on the initial
concentration. Nevertheless, the largest degradation of
EVs appeared during the freeze-thaw cycles, and subse-
quent sequencing results also reflect this. Similarly, by
DNA electrophoresis we showed that with the deterior-
ation of conditions, such as 4 °C for 168 h, room
temperature for 48 h and repeated freezing and thawing
five times, the serum without intact EVs began to show
increasing amounts of DNA products, which implies
the rupture of EVs. Also, primer differences exist be-
tween different patients under various conditions. Im-
portantly, exosomes are recognized as promising
diagnostic and predictive biomarkers in cancer. There-
fore, clinicians might use them to guide individual
treatments [51]. Our research confirmed that EVs or
exosomes exhibit extremely stable characteristics and
can protect themselves from material damage by the
external environment. EVs show a considerable degree
of consistency with tumor cells on the detection of gen-
etic mutation. Therefore EVs may be a suitable choice
for genetic testing and/or guiding the individual treat-
ment of a patient.
Conclusions
In conclusion, Serum EVs, and EVs DNA can remain
stable under different storage environments, which is
the premise that EVs could be serve as a novel means
for tumor genetic detection and potential biomarkers for
cancer diagnostics and prognostics. Furthermore, maybe
we can monitor changes in EVs gene during patients
treatment to better guide individualized therapy.
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